---
document_datetime: 2025-12-02 04:52:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-mylan.html
document_name: sitagliptin-metformin-hydrochloride-mylan.html
version: success
processing_time: 0.1238972
conversion_datetime: 2025-12-24 19:56:43.553606
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sitagliptin / Metformin hydrochloride Mylan

[RSS](/en/individual-human-medicine.xml/67522)

##### Authorised

This medicine is authorised for use in the European Union

sitagliptin hydrochloride monohydrate / metformin hydrochloride Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sitagliptin / Metformin hydrochloride Mylan](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79764)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sitagliptin/Metformin hydrochloride Mylan is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes. It is used together with diet and exercise in the following ways: • in patients whose blood glucose levels are not satisfactorily controlled with metformin (a diabetes medicine) used on its own; • in patients who are already taking a combination of sitagliptin and metformin as separate tablets; • in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin (other types of diabetes medicines) in patients whose blood glucose levels are not satisfactorily controlled with either of these medicines and metformin. Sitagliptin/Metformin hydrochloride Mylan contains the active substances sitagliptin and metformin hydrochloride and is a 'generic medicine'. This means that Sitagliptin/Metformin hydrochloride Mylan contains the same active substances and works in the same way as a 'reference medicine' already authorised in the EU called Janumet. For more information on generic medicines, see the question-and-answer document here.

Expand section

Collapse section

## How is Sitagliptin/Metformin hydrochloride Mylan used?

Sitagliptin/Metformin hydrochloride Mylan is available as tablets and can only be obtained with a prescription. The medicine is taken twice a day and the strength of the tablet depends on the dose of the other diabetes medicines that the patient was taking before. If Sitagliptin/Metformin hydrochloride Mylan is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered to avoid hypoglycaemia (low blood sugar levels). The maximum dose of sitagliptin is 100 mg a day. Sitagliptin/Metformin hydrochloride Mylan should be taken with food to avoid any stomach problems caused by metformin.

## How does Sitagliptin/Metformin hydrochloride Mylan work?

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or where the body is unable to use insulin effectively. The active substances in Sitagliptin/Metformin hydrochloride Mylan each have a different mode of action.

## How has Sitagliptin/Metformin hydrochloride Mylan been studied?

Studies on the benefits and risks of the active substances in the authorised use have already been carried out with the reference medicine, Janumet, and do not need to be repeated for Sitagliptin/Metformin hydrochloride Mylan. As for every medicine, the company provided data on the quality of Sitagliptin/Metformin hydrochloride Mylan. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Sitagliptin/Metformin hydrochloride Mylan?

Because Sitagliptin/Metformin hydrochloride Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Sitagliptin/Metformin hydrochloride Mylan authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sitagliptin/Metformin hydrochloride Mylan has been shown to have comparable quality and to be bioequivalent to Janumet. Therefore, the Agency's view was that, as for Janumet, the benefits of Sitagliptin/Metformin hydrochloride Mylan outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sitagliptin/Metformin hydrochloride Mylan?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sitagliptin/Metformin hydrochloride Mylan have been included in the summary of product characteristics and the package leaflet. As for all medicines, data on the use of Sitagliptin/Metformin hydrochloride Mylan are continuously monitored. Suspected side effects reported with Sitagliptin/Metformin hydrochloride Mylan are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sitagliptin/Metformin hydrochloride Mylan

Sitagliptin/Metformin hydrochloride Mylan received a marketing authorisation valid throughout the EU on 16 February 2022.

Sitagliptin / Metformin hydrochloride Mylan : EPAR - Medicine Overview

Reference Number: EMA/2302/2022

English (EN) (161.21 KB - PDF)

**First published:** 08/03/2022

[View](/en/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-341)

български (BG) (184.95 KB - PDF)

**First published:**

08/03/2022

[View](/bg/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_bg.pdf)

español (ES) (160.23 KB - PDF)

**First published:**

08/03/2022

[View](/es/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (188.46 KB - PDF)

**First published:**

08/03/2022

[View](/cs/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (159.2 KB - PDF)

**First published:**

08/03/2022

[View](/da/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (163.39 KB - PDF)

**First published:**

08/03/2022

[View](/de/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (158.17 KB - PDF)

**First published:**

08/03/2022

[View](/et/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (194.91 KB - PDF)

**First published:**

08/03/2022

[View](/el/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_el.pdf)

français (FR) (161.57 KB - PDF)

**First published:**

08/03/2022

[View](/fr/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (180.3 KB - PDF)

**First published:**

08/03/2022

[View](/hr/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (158.29 KB - PDF)

**First published:**

08/03/2022

[View](/it/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (201.28 KB - PDF)

**First published:**

08/03/2022

[View](/lv/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (180.8 KB - PDF)

**First published:**

08/03/2022

[View](/lt/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (180.81 KB - PDF)

**First published:**

08/03/2022

[View](/hu/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (184.78 KB - PDF)

**First published:**

08/03/2022

[View](/mt/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (160.65 KB - PDF)

**First published:**

08/03/2022

[View](/nl/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (185.33 KB - PDF)

**First published:**

08/03/2022

[View](/pl/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_pl.pdf)

português (PT) (160.65 KB - PDF)

**First published:**

08/03/2022

[View](/pt/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_pt.pdf)

română (RO) (178.87 KB - PDF)

**First published:**

08/03/2022

[View](/ro/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (181.43 KB - PDF)

**First published:**

08/03/2022

[View](/sk/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (178.15 KB - PDF)

**First published:**

08/03/2022

[View](/sl/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (157.7 KB - PDF)

**First published:**

08/03/2022

[View](/fi/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (158.39 KB - PDF)

**First published:**

08/03/2022

[View](/sv/documents/overview/sitagliptin-metformin-hydrochloride-mylan-epar-medicine-overview_sv.pdf)

Sitagliptin / Metformin hydrochloride Mylan : EPAR - Risk management plan summary

English (EN) (77.65 KB - PDF)

**First published:** 08/03/2022

[View](/en/documents/rmp-summary/sitagliptin-metformin-hydrochloride-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Sitagliptin / Metformin hydrochloride Mylan : EPAR - Product Information

English (EN) (457.61 KB - PDF)

**First published:** 08/03/2022

**Last updated:** 30/09/2025

[View](/en/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-535)

български (BG) (650.02 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/bg/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_bg.pdf)

español (ES) (507.96 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/es/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_es.pdf)

čeština (CS) (598.46 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/cs/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_cs.pdf)

dansk (DA) (548.45 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/da/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_da.pdf)

Deutsch (DE) (485.03 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/de/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_de.pdf)

eesti keel (ET) (546.32 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/et/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (407 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/el/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_el.pdf)

français (FR) (322.06 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/fr/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (635.96 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/hr/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_hr.pdf)

íslenska (IS) (522.56 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/is/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_is.pdf)

italiano (IT) (473.37 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/it/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (439.08 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/lv/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (494.49 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/lt/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_lt.pdf)

magyar (HU) (536.11 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/hu/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_hu.pdf)

Malti (MT) (687.24 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/mt/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (553.55 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/nl/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_nl.pdf)

norsk (NO) (427.6 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/no/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_no.pdf)

polski (PL) (548.26 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/pl/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_pl.pdf)

português (PT) (467.74 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/pt/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_pt.pdf)

română (RO) (524.57 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/ro/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (643.09 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/sk/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (409.1 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/sl/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_sl.pdf)

Suomi (FI) (528.77 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/fi/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_fi.pdf)

svenska (SV) (684.95 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

30/09/2025

[View](/sv/documents/product-information/sitagliptin-metformin-hydrochloride-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000302331 30/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sitagliptin / Metformin hydrochloride Mylan : EPAR - All authorised presentations

English (EN) (17.82 KB - PDF)

**First published:** 08/03/2022

**Last updated:** 21/06/2022

[View](/en/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-392)

български (BG) (49.79 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/bg/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (71.48 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/es/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.49 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/cs/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.12 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/da/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (62.21 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/de/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.26 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/et/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.14 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/el/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (56.9 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/fr/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (110.12 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/hr/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.17 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/is/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (60.16 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/it/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (71.49 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/lv/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (66.98 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/lt/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.83 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/hu/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (65.9 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/mt/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.92 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/nl/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (43.83 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/no/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (62.41 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/pl/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (86.97 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/pt/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.7 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/ro/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (63.99 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/sk/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (62.7 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/sl/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.25 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/fi/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.31 KB - PDF)

**First published:**

08/03/2022

**Last updated:**

21/06/2022

[View](/sv/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sitagliptin / Metformin hydrochloride Mylan Active substance

- sitagliptin hydrochloride monohydrate
- metformin hydrochloride

International non-proprietary name (INN) or common name

- sitagliptin hydrochloride monohydrate
- metformin hydrochloride

Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BD07

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

| For adult patients with type 2 diabetes mellitus:  Sitagliptin/Metformin hydrochloride Mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.  Sitagliptin/Metformin hydrochloride Mylan is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.  Sitagliptin/Metformin hydrochloride Mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARg) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARg agonist.  Sitagliptin/Metformin hydrochloride Mylan is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Authorisation details

EMA product number EMEA/H/C/005678

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park,

Opinion adopted 16/12/2021 Marketing authorisation issued 16/02/2022 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sitagliptin / Metformin hydrochloride Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (402.81 KB - PDF)

**First published:** 04/04/2025

**Last updated:** 30/09/2025

[View](/en/documents/procedural-steps-after/sitagliptin-metformin-hydrochloride-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sitagliptin / Metformin hydrochloride Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (159.8 KB - PDF)

**First published:** 21/06/2022

**Last updated:** 04/04/2025

[View](/en/documents/steps-after-cutoff/sitagliptin-metformin-hydrochloride-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sitagliptin / Metformin hydrochloride Mylan : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/27581/2022

English (EN) (526.76 KB - PDF)

**First published:** 08/03/2022

[View](/en/documents/assessment-report/sitagliptin-metformin-hydrochloride-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sitagliptin / Metformin hydrochloride Mylan

Adopted

Reference Number: EMA/CHMP/732596/2021

English (EN) (155.11 KB - PDF)

**First published:** 17/12/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sitagliptin-metformin-hydrochloride-mylan_en.pdf)

#### News on Sitagliptin / Metformin hydrochloride Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021) 17/12/2021

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Sitagliptin/Metformin hydrochloride Mylan : EPAR - Product information - tracked changes

English (EN) (161.65 KB - DOCX)

**First published:** 30/09/2025

[View](/en/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-816)

български (BG) (198.88 KB - DOCX)

**First published:**

30/09/2025

[View](/bg/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_bg.docx)

español (ES) (186.02 KB - DOCX)

**First published:**

30/09/2025

[View](/es/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_es.docx)

čeština (CS) (156.29 KB - DOCX)

**First published:**

30/09/2025

[View](/cs/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (156.91 KB - DOCX)

**First published:**

30/09/2025

[View](/da/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (148.88 KB - DOCX)

**First published:**

30/09/2025

[View](/de/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (145.32 KB - DOCX)

**First published:**

30/09/2025

[View](/et/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (205.43 KB - DOCX)

**First published:**

30/09/2025

[View](/el/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_el.docx)

français (FR) (161.08 KB - DOCX)

**First published:**

30/09/2025

[View](/fr/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (195.03 KB - DOCX)

**First published:**

30/09/2025

[View](/hr/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (148.56 KB - DOCX)

**First published:**

30/09/2025

[View](/is/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_is.docx)

italiano (IT) (163.12 KB - DOCX)

**First published:**

30/09/2025

[View](/it/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (164.79 KB - DOCX)

**First published:**

30/09/2025

[View](/lv/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (148.93 KB - DOCX)

**First published:**

30/09/2025

[View](/lt/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (170.19 KB - DOCX)

**First published:**

30/09/2025

[View](/hu/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (198.3 KB - DOCX)

**First published:**

30/09/2025

[View](/mt/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (171.77 KB - DOCX)

**First published:**

30/09/2025

[View](/nl/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (154.95 KB - DOCX)

**First published:**

30/09/2025

[View](/no/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_no.docx)

polski (PL) (183.89 KB - DOCX)

**First published:**

30/09/2025

[View](/pl/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_pl.docx)

português (PT) (171.52 KB - DOCX)

**First published:**

30/09/2025

[View](/pt/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_pt.docx)

română (RO) (171.38 KB - DOCX)

**First published:**

30/09/2025

[View](/ro/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (176.37 KB - DOCX)

**First published:**

30/09/2025

[View](/sk/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (147.12 KB - DOCX)

**First published:**

30/09/2025

[View](/sl/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (164.39 KB - DOCX)

**First published:**

30/09/2025

[View](/fi/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (269.28 KB - DOCX)

**First published:**

30/09/2025

[View](/sv/documents/product-information-tracked-changes/sitagliptin-metformin-hydrochloride-mylan-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 30/09/2025

## Share this page

[Back to top](#main-content)